IM Therapeutics
PrivateLast Round
Series A
Oct 9, 2019
Total Funding Raised
$10.23M
Company Overview
IM Therapeutics is a clinical-stage biopharmaceutical company that develops personalized oral therapies for autoimmune diseases by targeting human leukocyte antigen (HLA) gene variants.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
IM Therapeutics Comparables
Compare IM Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Phaim Pharma | 84% | |
| Imcyse | 81% | |
| Anokion | 74% |
IM Therapeutics Funding Rounds
Historical fundraising activity
IM Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| Morningside Ventures | Series A |
| JDRF | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 9, 2019
$10M round led by Morningside Ventures and JDRF.
- Nov 14, 2018
$225K grant received from Americas Seed Fund and NIH RADx.
IM Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about IM Therapeutics's valuation, stock price, and market status.
Is IM Therapeutics a public or private company?
IM Therapeutics is a private company.
What is the current stock price of IM Therapeutics?
IM Therapeutics is a private company, so its shares have no public market price. Caplight tracks IM Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is IM Therapeutics worth (valuation)?
Valuation information for IM Therapeutics is not publicly available.
Can I buy IM Therapeutics stock?
IM Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was IM Therapeutics's last funding round?
IM Therapeutics's most recent funding round was Series A on October 9, 2019.
Who are the main investors in IM Therapeutics?
Key investors in IM Therapeutics include Morningside Ventures, JDRF.
Will IM Therapeutics IPO soon?
No public IPO plans have been announced for IM Therapeutics.
How can I track IM Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in IM Therapeutics's shares on secondary markets.